{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.7","upperLimit":"8.9","value":"7.3"},{"groupId":"OG001","lowerLimit":"3.8","upperLimit":"18.8","value":"7.7"},{"groupId":"OG002","lowerLimit":"6.1","upperLimit":"12.8","value":"9.3"},{"groupId":"OG003","lowerLimit":"8.5","upperLimit":"18.5","value":"12.0"},{"groupId":"OG004","lowerLimit":"2.7","upperLimit":"17.4","value":"9.2"},{"groupId":"OG005","lowerLimit":"2.1","upperLimit":"12.1","value":"5.7"},{"comment":"Not reached","groupId":"OG006","lowerLimit":"8.7","upperLimit":"NA","value":"16.1"},{"groupId":"OG007","lowerLimit":"3.4","upperLimit":"16.2","value":"7.4"},{"groupId":"OG008","lowerLimit":"6.5","upperLimit":"10.9","value":"8.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"21"},{"groupId":"OG007","value":"31"},{"groupId":"OG008","value":"105"}],"units":"Participants"}],"description":"Overall survival defined as the period of time from the date of first infusion to the date of death or last contact in case of patients lost to follow-up or alive at the clinical cutoff established for the cohort.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with Pathologically proven diagnosis of biliary tract carcinoma","id":"OG000","title":"Biliary Tract Carcinoma Cohort"},{"description":"Patients with pathologically proven diagnosis of carcinoma of unknown primary site","id":"OG001","title":"Carcinoma of Unknown Primary Site Cohort"},{"description":"Patients with pathologically proven diagnosis of endometrial carcinoma","id":"OG002","title":"Endometrial Carcinoma Cohort"},{"description":"Patients with pathologically proven diagnosis of Ewing's Family of Tumors","id":"OG003","title":"Ewing's Family of Tumors Cohort"},{"description":"Patients with pathologically proven diagnosis of Germ Cell Tumors, excluding immature teratoma, or teratoma with malignant transformation.","id":"OG004","title":"Germ Cell Tumors Cohort"},{"description":"Patients with Pathologically proven diagnosis of Head and Neck Carcinoma. Salivary glands tumors were excluded.","id":"OG005","title":"Head and Neck Carcinoma Cohort"},{"description":"Patients with pathologically proven diagnosis of BRCA1/2-associated metastatic breast carcinoma","id":"OG006","title":"BRCA1/2-associated Metastatic Breast Carcinoma Cohort"},{"description":"Patients with Pathologically proven diagnosis of Neuroendocrine Tumors, grade 2 and 3 according to World Health Organization (WHO) classification.","id":"OG007","title":"Neuroendocrine Tumors Cohort"},{"description":"Patients with pathologically proven diagnosis of small cell lung cancer","id":"OG008","title":"Small Cell Lung Cancer Cohort"}],"paramType":"MEDIAN","populationDescription":"Treated patients with disease measurement","reportingStatus":"POSTED","timeFrame":"From the date of first infusion to the date of death or last contact, up to an average of 5 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}